Evidence map›Paper›PMID 41610211›Full record

ArticleInternational journal of surgical pathology2026

Radiotherapy Response Prediction in Myxofibrosarcomas and Undifferentiated Soft Tissue Sarcomas Using DNA Methylation and Copy Number Profiling.

Tony G Kleijn, Baptiste Ameline, Wierd Kooistra, Léon C van Kempen, Gilles F H Diercks, Robert J van Ginkel, Lukas B Been, Barbara L van Leeuwen, Anna K L Reyners, Thomas C Kwee and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of surgical pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Tony G KleijnDepartment of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0001-5436-8765
Baptiste AmelineBone Tumor Reference Center at the Institute for Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
Wierd KooistraDepartment of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Léon C van KempenDepartment of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0003-0646-0705
Gilles F H DiercksDepartment of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Robert J van GinkelDepartment of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Lukas B BeenDepartment of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Barbara L van LeeuwenDepartment of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Anna K L ReynersDepartment of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Thomas C KweeDepartment of Radiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Paul C JutteDepartment of Orthopedic Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Joris J W PloegmakersDepartment of Orthopedic Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0002-1644-4015
Henk BijlDepartment of Radiotherapy, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Bart VanhautenDepartment of Radiotherapy, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
J Fred UbbelsDepartment of Radiotherapy, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Ed SchuuringDepartment of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Albert J H SuurmeijerDepartment of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Jacco J de HaanDepartment of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Daniel BaumhoerBone Tumor Reference Center at the Institute for Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
Arjen H G ClevenDepartment of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundMyxofibrosarcoma (MFS) and undifferentiated soft tissue sarcoma (USTS) are common sarcoma subtypes with overlapping molecular features. Both are treated with neoadjuvant radiotherapy followed by surgery, yet radiotherapy response is variable and unpredictable. This study investigated DNA methylation and copy number variation (CNV) profiles obtained from pre-radiotherapy biopsies as predictive biomarkers of radiotherapy response.Patients and methodsPre-radiotherapy biopsies and post-radiotherapy resections were obtained from 49 patients (27 MFS, 22 USTS). Radiotherapy response was assessed on the resection specimens using the EORTC-STBSG 5-tier system; grades A-C (<10% viable tumor) were classified as responders, D-E (≥10% viable tumor) as non-responders. Genome-wide DNA methylation and CNV data were generated from the pre-radiotherapy biopsies using Illumina MethylationEPIC BeadChips and were correlated with response grades.ResultsDNA methylation profiling yielded evaluable results in 23/49 tumors (15 MFS, 8 USTS), with 9 responders and 14 non-responders. Unsupervised methylation clustering, incorporating public datasets, showed that MFS, USTS, and pleomorphic liposarcomas formed a single, heterogeneous cluster. Similarly, CNV profiles did not distinguish MFS from USTS. Methylation patterns did not significantly differ between responders and non-responders. CNV profiles were largely comparable between responders and non-responders, except of a significantly higher frequency of chromosome 11q24.1 loss in responders compared to non-responders (100% vs 33%; P = 0.0039).ConclusionsOur findings support the concept that MFS and USTS represent a spectrum of the same disease. We could not demonstrate the value of DNA methylation profiling in radiotherapy response prediction. However, 11q24.1 loss may represent a potential predictive biomarker and merits further validation.

Indexed as

DNA Copy Number VariationsDNA MethylationFibrosarcomaSarcomaSoft Tissue NeoplasmsAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansMaleMiddle AgedNeoadjuvant TherapyTreatment OutcomeYoung AdultBiomarkers, Tumorcopy number variationDNA methylationmyxofibrosarcomaprofilingradiotherapy responseundifferentiated soft tissue sarcoma

Identifiers

PMID41610211
PMCPMC13168605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.